WallStreetZenWallStreetZen

NASDAQ: DMAC
Diamedica Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for DMAC

Based on 2 analysts offering 12 month price targets for Diamedica Therapeutics Inc.
Min Forecast
$6.00+150%
Avg Forecast
$7.00+191.67%
Max Forecast
$8.00+233.33%

Should I buy or sell DMAC stock?

Based on 2 analysts offering ratings for Diamedica Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their DMAC stock forecasts and price targets.

DMAC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-24
lockedlocked$00.00+00.00%2024-03-21

1 of 1

Forecast return on equity

Is DMAC forecast to generate an efficient return?
Company
-54.88%
Industry
28.88%
Market
26.18%
DMAC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DMAC forecast to generate an efficient return on assets?
Company
-51.64%
Industry
5.9%
DMAC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DMAC earnings per share forecast

What is DMAC's earnings per share in the next 1 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$0.67

DMAC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DMAC$2.40$7.00+191.67%Buy
RLMD$3.01$2.00-33.55%Strong Sell
ORMP$2.25N/AN/A
IFRX$1.56$8.00+412.82%Buy
SER$11.01N/AN/A

Diamedica Therapeutics Stock Forecast FAQ

Is Diamedica Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: DMAC) stock is to Buy DMAC stock.

Out of 2 analysts, 0 (0%) are recommending DMAC as a Strong Buy, 2 (100%) are recommending DMAC as a Buy, 0 (0%) are recommending DMAC as a Hold, 0 (0%) are recommending DMAC as a Sell, and 0 (0%) are recommending DMAC as a Strong Sell.

If you're new to stock investing, here's how to buy Diamedica Therapeutics stock.

What is DMAC's earnings growth forecast for 2024-2024?

(NASDAQ: DMAC) Diamedica Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.

Diamedica Therapeutics's earnings in 2024 is -$19,270,000.

In 2024, DMAC is forecast to generate -$25,435,824 in earnings, with the lowest earnings forecast at -$25,435,824 and the highest earnings forecast at -$25,435,824.

What is DMAC's forecast return on equity (ROE) for 2024-2024?

(NASDAQ: DMAC) forecast ROE is -54.88%, which is considered weak.

What is DMAC's Price Target?

According to 2 Wall Street analysts that have issued a 1 year DMAC price target, the average DMAC price target is $7.00, with the highest DMAC stock price forecast at $8.00 and the lowest DMAC stock price forecast at $6.00.

On average, Wall Street analysts predict that Diamedica Therapeutics's share price could reach $7.00 by Apr 24, 2025. The average Diamedica Therapeutics stock price prediction forecasts a potential upside of 191.67% from the current DMAC share price of $2.40.

What is DMAC's Earnings Per Share (EPS) forecast for 2024-2024?

(NASDAQ: DMAC) Diamedica Therapeutics's current Earnings Per Share (EPS) is -$0.56. In 2024, DMAC's EPS is forecast to hit -$0.67 (min: -$0.67, max: -$0.67).

What is DMAC's forecast return on assets (ROA) for 2024-2024?

(NASDAQ: DMAC) forecast ROA is -51.64%, which is lower than the forecast US Biotechnology industry average of 5.9%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.